Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort. Sanchez-Bayona R, Lopez de Sa A, Jerez Gilarranz Y, Sanchez de Torre A, et al. Breast Cancer Res Treat 2024 May 4. doi: 10.1007/s10549-024-07324.

Read + Share

Amedeo Smart

Independent Medical Education

Sanchez-Bayona R, Lopez de Sa A, Jerez Gilarranz Y, Sanchez de Torre A, et al. Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort. Breast Cancer Res Treat 2024 May 4. doi: 10.1007/s10549-024-07324.
PMID: 38703285